Insulin resistance and outcome in bipolar disorder

British Journal of Psychiatry

Volumn 206, Issue 1, 2015, Pages 52-57

  Calkin, Cynthia V ^a   Ruzickova, Martina ^a   Uher, Rudolf ^a,b   Hajek, Tomas ^a,c   Slaney, Claire M ^d   Garnham, Julie S ^d   O'Donovan, M Claire ^a   Alda, Martin ^a,c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Capital District Health Authority ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; LITHIUM; GLUCOSE BLOOD LEVEL; TRANQUILIZER;

ADULT; AGE; AGED; ARTICLE; BIPOLAR DISORDER; BODY MASS; CARDIOMETABOLIC RISK; COMPARATIVE STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EXPOSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIGH RISK PATIENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LITHIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; OUTCOME ASSESSMENT; PROPHYLAXIS; PSYCHOPHARMACOTHERAPY; REFRACTORY PERIOD; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT RESPONSE; ADOLESCENT; BLOOD; CASE CONTROL STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIMANIC AGENTS; BIPOLAR DISORDER; BLOOD GLUCOSE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; LITHIUM; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920502045     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.114.152850     Document Type: Article

References (32)

1. Cassidy F, Ahearn E, Carroll BJ. Elevated frequency of diabetes mellitus in hospitalized manic-depressive patients. Am J Psychiatry 1999; 156: 1417-20.
2. Lilliker SL. Prevalence of diabetes in a manic-depressive population. Compr Psychiatry 1980; 21: 270-5.
3. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17: 83-93.
4. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 5: 844-50.
5. Ruzickova M, Slaney C, Garnham J, Alda M. Clinical features of bipolar disorder with and without comorbid diabetes mellitus. Can J Psychiatry 2003; 48: 458-61.
6. Calkin C, Van de Velde C, Ruzickova M, Slaney C, Garnham J, Hajek T, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord 2009; 11: 650-6.
7. Kemp DE, Gao K, Chan PK, Ganocy SJ, Findling RL, Calabrese JR. Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome. Bipolar Disord 2010; 12: 404-13.
8. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978; 35: 837-44.
9. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria: rationale and reliability. Arch Gen Psychiatry 1978; 35: 773-82.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). APA, 2000.
11. Rucker J, Newman S, Gray J, Gunasinghe C, Broadbent M, Brittain P, et al. OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings. Br J Psychiatry 2011; 199: 151-5.
12. Denicoff KD, Leverich GS, Nolen WA, Rush AJ, McElroy SL, Keck PE, et al. Validation of the prospective NIMH-Life-Chart Method (NIMH-LCM-p) for longitudinal assessment of bipolar illness. Psychol Med 2000; 30: 1391-7.
13. Denicoff KD, Ali SO, Sollinger AB, Smith-Jackson EE, Leverich GS, Post RM. Utility of the daily prospective National Institute of Mental Health Life-Chart Method (NIMH-LCM-p) ratings in clinical trials of bipolar disorder. Depress Anxiety 2002; 15: 1-9.
14. Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002; 63: 942-7.
15. Garnham J, Munro A, Slaney C, MacDougall M, Passmore M, Duffy A, et al. Prophylactic treatment response in bipolar disorder: results of a naturalistic observation study. J Affect Disord 2007; 104: 185-90.
16. Manchia M, Adli M, Akula N, Ardau R, Aubry JM, Backlund L, et al. Assessment of response to lithium maintenance treatment in bipolar disorder: a Consortium on Lithium Genetics (ConLiGen) report. PLoS One 2013; 8: e65636.
17. Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale - reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995; 166: 654-9.
18. Andreasen NC, Endicott J, Spitzer RL, Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry 1977; 34: 1229-35.
19. Katsuki A, Sumida Y, Gabazza EC, Murashima S, Furuta M, Araki-Sasaki R, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care 2001; 24: 362-5.
20. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-95.
21. Esteghamati A, Ashraf H, Khalilzadeh O, Zandieh A, Nakhjavani M, Rashidi A, et al. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab 2010; 7: 26-33.
22. Wongwananuruk T, Rattanachaiyanont M, Leerasiri P, Indhavivadhana S, Techatraisak K, Angsuwathana S, et al. The usefulness of homeostatic measurement assessment-insulin resistance (HOMA-IR) for detection of glucose intolerance in Thai women of reproductive age with polycystic ovary syndrome. Int J Endocrinol 2012; 57: 10-35.
23. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
24. Uher R, Tansey KE, Malki K, Perlis RH. Biomarkers predicting treatment outcome in depression: what is clinically significant? Pharmacogenomics 2012; 13: 233-40.
25. Yood MU, DeLorenze G, Quesenberry CP Jr, Oliveria SA, Tsai AL, Willey VJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent: results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009; 18: 791-9.
26. Wallum BJ, Taborsky GJ Jr, Porte D Jr, Figlewicz DP, Jacobson L, Beard JC, et al. Cerebrospinal fluid insulin levels increase during intravenous insulin infusions in man. J Clin Endocrinol Metab 1987; 64: 190-4.
27. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 2004; 3: 169-78.
28. Hajek T, Calkin C, Blagdon R, Slaney C, Alda M. Type 2 Diabetes mellitus: a potentially modifiable risk factor for neurochemical brain changes in bipolar disorders. Biol Psychiatry 2013; Nov 13 (Epub ahead of print).
29. Hajek T, Calkin C, Blagdon R, Slaney C, Uher R, Alda M. Insulin resistance, diabetes mellitus and brain structure in bipolar disorders. Neuropsychopharmacology 2014; June 19 (Epub ahead of print).
30. McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS, et al. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord 2010; 126: 366-87.
31. Kaidanovich-Beilin O, Cha DS, McIntyre RS. Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep 2012; 4: 14-24.
32. Calkin CV, Gardner DM, Ransom T, Alda M. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med 2012; 45: 171-81.